Chelation therapy is central to managing iron overload. This post explains what chelators are, how they bind excess metal, and why selectivity matters for safety.
What is a Chelator? #
A chelator is a molecule that binds a metal ion through multiple donor atoms simultaneously, forming a stable ring-shaped complex (the word "chelate" comes from the Greek for "claw"). In pharmacology, iron chelators are designed to bind excess ferric (Fe3+) iron and promote its elimination.
Coordination Numbers #
- Bidentate chelators (e.g. deferiprone) provide 2 donor atoms - 3 molecules bind 1 Fe3+ (3:1)
- Tridentate chelators (e.g. deferasirox) provide 3 donor atoms - 2 molecules bind 1 Fe3+ (2:1)
- Hexadentate chelators (e.g. deferoxamine) provide 6 donor atoms - 1 molecule binds 1 Fe3+ (1:1)
Higher denticity generally gives more stable complexes at a given molar ratio.
Why Selectivity Matters #
An effective iron chelator must prefer Fe3+ over essential metals like zinc, copper and calcium. Deferasirox shows high selectivity for Fe3+, supporting long-term safety.
Neutralising Redox Activity #
Free iron catalyses Fenton reactions that produce damaging hydroxyl radicals. A well-formed chelator-iron complex is redox-inactive, breaking this damage cycle.
Excretion Routes #
- Biliary / faecal (deferasirox) - useful in patients with renal impairment considerations
- Renal / urinary (deferoxamine) - depends on renal function
Clinical Translation #
The ideal chelator is: oral, once-daily, highly selective for Fe3+, well tolerated in long-term use, and effective across the body's iron storage compartments (liver, heart, endocrine glands). Deferasirox approaches this profile and is the standard of care in transfusional iron overload.